Oncolytics files for Reolysin Ph I/II trial

Canada's Oncolytics Biotech says that the US National Cancer Institute has filed a protocol with the Food and Drug Administration for a Phase I/II clinical trial for patients with metastatic ovarian, peritoneal or fallopian tube cancers using concurrent systemic and intraperitoneal administration of Reolysin, the firm's proprietary formulation of the human reovirus. The NCI is sponsoring the trial under its Clinical Trials Agreement with Oncolytics, while the latter will provide clinical supplies of the agent.

The trial, which is being carried out at the Ohio State University Comprehensive Cancer Center, is expected to enroll up to 70 patients with metastatic ovarian, peritoneal or fallopian tube cancers. These cancer indications were selected after comprehensive preclinical studies carried out by the NCI indicated the reovirus can kill ovarian cancer cells.